BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $13,896,000 | +95.0% | 179,212 | +115.9% | 0.60% | +107.3% |
| Q4 2021 | $7,126,000 | +6.0% | 83,011 | -0.7% | 0.29% | -0.7% |
| Q3 2021 | $6,722,000 | +0.3% | 83,577 | +0.4% | 0.29% | 0.0% |
| Q2 2021 | $6,701,000 | -2.3% | 83,248 | +2.4% | 0.29% | -11.1% |
| Q1 2021 | $6,858,000 | +1.8% | 81,313 | -3.2% | 0.32% | -2.7% |
| Q4 2020 | $6,740,000 | -1.0% | 83,998 | -0.8% | 0.33% | -16.7% |
| Q3 2020 | $6,811,000 | -43.8% | 84,692 | -39.8% | 0.40% | -47.9% |
| Q2 2020 | $12,110,000 | +7.3% | 140,650 | +1.2% | 0.77% | -9.2% |
| Q1 2020 | $11,289,000 | -2.6% | 139,044 | +0.3% | 0.85% | +20.5% |
| Q4 2019 | $11,591,000 | -26.5% | 138,619 | -23.2% | 0.70% | -31.6% |
| Q3 2019 | $15,778,000 | +126.7% | 180,384 | +112.3% | 1.03% | +122.7% |
| Q2 2019 | $6,960,000 | +2.1% | 84,986 | +1.3% | 0.46% | +0.9% |
| Q1 2019 | $6,819,000 | +24.6% | 83,861 | +0.8% | 0.46% | +9.3% |
| Q4 2018 | $5,474,000 | -53.9% | 83,167 | -46.0% | 0.42% | -47.4% |
| Q3 2018 | $11,868,000 | +4.4% | 153,946 | -0.0% | 0.80% | -2.8% |
| Q2 2018 | $11,371,000 | +13.1% | 153,996 | -0.4% | 0.82% | +10.8% |
| Q1 2018 | $10,058,000 | -0.2% | 154,639 | -0.8% | 0.74% | +1.5% |
| Q4 2017 | $10,081,000 | -0.4% | 155,949 | -3.3% | 0.73% | -4.0% |
| Q3 2017 | $10,124,000 | +4.6% | 161,339 | +0.9% | 0.76% | -0.4% |
| Q2 2017 | $9,676,000 | +14.2% | 159,824 | -2.2% | 0.76% | +11.6% |
| Q1 2017 | $8,473,000 | -13.8% | 163,389 | -26.3% | 0.68% | -18.9% |
| Q4 2016 | $9,832,000 | -5.4% | 221,735 | +1.6% | 0.84% | -7.1% |
| Q3 2016 | $10,393,000 | +79.7% | 218,335 | +70.7% | 0.90% | +75.0% |
| Q2 2016 | $5,785,000 | +806.7% | 127,925 | +724.3% | 0.52% | +747.5% |
| Q1 2016 | $638,000 | +6.0% | 15,520 | -1.6% | 0.06% | +3.4% |
| Q4 2015 | $602,000 | +15.5% | 15,770 | -0.5% | 0.06% | +7.3% |
| Q3 2015 | $521,000 | -49.8% | 15,850 | +6.7% | 0.06% | -45.5% |
| Q2 2015 | $1,038,000 | +2.1% | 14,850 | 0.0% | 0.10% | +2.0% |
| Q1 2015 | $1,017,000 | -14.3% | 14,850 | -8.3% | 0.10% | -18.9% |
| Q4 2014 | $1,187,000 | +34.1% | 16,200 | +31.4% | 0.12% | +25.8% |
| Q3 2014 | $885,000 | -82.1% | 12,325 | -82.0% | 0.10% | -82.4% |
| Q2 2014 | $4,947,000 | 0.0% | 68,426 | +1.8% | 0.55% | -7.7% |
| Q1 2014 | $4,947,000 | +5.6% | 67,230 | -0.2% | 0.60% | +7.0% |
| Q4 2013 | $4,686,000 | -12.0% | 67,370 | -16.8% | 0.56% | -23.8% |
| Q3 2013 | $5,322,000 | +13.2% | 81,010 | +19.4% | 0.73% | -11.6% |
| Q2 2013 | $4,701,000 | – | 67,865 | – | 0.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |